Zhichen Sun

2.0k total citations · 2 hit papers
32 papers, 1.5k citations indexed

About

Zhichen Sun is a scholar working on Immunology, Oncology and Biomedical Engineering. According to data from OpenAlex, Zhichen Sun has authored 32 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 18 papers in Oncology and 8 papers in Biomedical Engineering. Recurrent topics in Zhichen Sun's work include Immunotherapy and Immune Responses (15 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Zhichen Sun is often cited by papers focused on Immunotherapy and Immune Responses (15 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Zhichen Sun collaborates with scholars based in China and United States. Zhichen Sun's co-authors include Yang‐Xin Fu, Zhida Liu, Hua Peng, Jinming Gao, Jonathan Wilhelm, Baran D. Sumer, Suxin Li, Longchao Liu, Tongyi Huang and Qiang Feng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Zhichen Sun

30 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity

2022 254 citations Qiang Feng, Zhida Liu et al. Nature Communications profile →
STING licensing of type I dendritic cells potentiates antitumor immunity

2024 63 citations Suxin Li, Xu Wang et al. Science Immunology profile →

Peers

Countries citing papers authored by Zhichen Sun

Since Specialization

Citations

This map shows the geographic impact of Zhichen Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhichen Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhichen Sun more than expected).

Fields of papers citing papers by Zhichen Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhichen Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhichen Sun. The network helps show where Zhichen Sun may publish in the future.

Co-authorship network of co-authors of Zhichen Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Zhichen Sun. A scholar is included among the top collaborators of Zhichen Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhichen Sun. Zhichen Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers 2025 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), Gang Huang, Zhichen Sun, Qiang Feng, (unknown), (unknown), Baran D. Sumer, Jinming Gao	0
2	STING licensing of type I dendritic cells potentiates antitumor immunity breakdown → 2024 ·Science Immunology ·(unknown), Suxin Li, (unknown), Xu Wang, Shuqing Chen, Zhichen Sun, (unknown), Gang Huang, Baran D. Sumer, Nan Yan, Yang‐Xin Fu, Jinming Gao	63
3	Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors 2024 ·Biomaterials ·Tianyu Shi, Mengna Sun, (unknown), Mengru Li, Jiayu Wang, Yingxin Wang, Qinghua Zheng, (unknown), Changchang Lu, Zhichen Sun, Zhengyun Zou, Jie Shao, (unknown), Rutian Li, (unknown), (unknown)	3
4	Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors 2023 ·Advanced Science ·Xinyue Wang, Fanyan Meng, Xiang Li, (unknown), (unknown), (unknown), (unknown), Lin Li, (unknown), (unknown), Zhichen Sun, Yanhong Chu, (unknown), (unknown), Jie Shao, (unknown), Xiaoping Qian, Qin Liu, Baorui Liu, Rutian Li	14
5	Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (Adv. Sci. 12/2023) 2023 ·Advanced Science ·Xinyue Wang, (unknown), Xiang Li, (unknown), (unknown), (unknown), (unknown), Lin Li, (unknown), Yishan Li, Zhichen Sun, Yanhong Chu, Rui‐Hua Xu, Lixia Yu, Jie Shao, (unknown), Xiaoping Qian, Qin Liu, Baorui Liu, Rutian Li	1
6	Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor 2023 ·Bioengineering & Translational Medicine ·(unknown), (unknown), (unknown), Yuncheng Bei, Yanhong Chu, Zhichen Sun, Shiyao Du, Shujuan Zhou, Naiqing Ding, Fanyan Meng, Baorui Liu	6
7	Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity breakdown → 2022 ·Nature Communications ·Qiang Feng, Zhida Liu, Xuexin Yu, Tongyi Huang, Jiahui Chen, Jian Wang, Jonathan Wilhelm, Suxin Li, (unknown), Wei Li, Zhichen Sun, Baran D. Sumer, Bo Li, Yang‐Xin Fu, Jinming Gao	254
8	In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors 2022 ·Journal of Hematology & Oncology ·Zhichen Sun, Rutian Li, Yun Shen, (unknown), Naiqing Ding, (unknown), Xinyue Wang, Jia Wei, Baorui Liu, Fanyan Meng	20
9	IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8+ T cells to overcome immunotherapy resistance in cancer 2022 ·Nature Cell Biology ·Joonbeom Bae, Longchao Liu, Casey Moore, Eric J. Hsu, Anli Zhang, Zhenhua Ren, Zhichen Sun, Xue Wang, Jiankun Zhu, (unknown), Jian Qiao, Yang‐Xin Fu	51
10	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy 2021 ·Nature Communications ·Eric J. Hsu, Xuezhi Cao, (unknown), Joonbeom Bae, Zhichen Sun, Zhida Liu, Yang‐Xin Fu	85
11	Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells 2021 ·Nature Biomedical Engineering ·Longchao Liu, Jiahui Chen, Joonbeom Bae, Huiyu Li, Zhichen Sun, Casey Moore, Eric J. Hsu, Chuanhui Han, Jian Qiao, Yang‐Xin Fu	57
12	Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window 2020 ·Nature Communications ·Xu Wang, Jonathan Wilhelm, Wei Li, Suxin Li, Zhaohui Wang, Gang Huang, Jian Wang, Houliang Tang, (unknown), Zhichen Sun, Bret M. Evers, Jinming Gao	79
13	<p>Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells</p> 2020 ·International Journal of Nanomedicine ·(unknown), Fangcen Liu, Lifeng Wang, Chen Xie, Puyuan Wu, Shiyao Du, Shujuan Zhou, Zhichen Sun, Qin Liu, Lixia Yu, Baorui Liu, Rutian Li	27
14	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells 2020 ·JCI Insight ·Sisi Deng, Zhichen Sun, Jian Qiao, Yong Liang, Longchao Liu, Chunbo Dong, Aijun Shen, Yang Wang, Hong Tang, Yang‐Xin Fu, Hua Peng	49
15	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control 2019 ·Nature Communications ·Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng	147
16	T cell-derived lymphotoxin limits Th1 response during HSV-1 infection 2018 ·Scientific Reports ·Kaiting Yang, Yong Liang, Zhichen Sun, Longchao Liu, Jing Liao, Hairong Xu, Mingzhao Zhu, Yang‐Xin Fu, Hua Peng	5
17	Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance 2018 ·Nature Communications ·Yong Liang, Haidong Tang, Jingya Guo, Xiangyan Qiu, (unknown), Zhenhua Ren, Zhichen Sun, Yingjie Bian, Lily Xu, Hairong Xu, (unknown), Yanfei Han, Haidong Dong, Hua Peng, Yang-Xin Fu	69
18	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression 2017 ·Cancer Immunology Research ·Jing Liao, Yan Luan, Zhenhua Ren, Xiaojuan Liu, (unknown), Hairong Xu, Zhichen Sun, Kaiting Yang, Hua Peng, Yang-Xin Fu	13
19	Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action 2017 ·Scientific Reports ·Yi Yu, Pin Wan, Yanhua Cao, Wei Zhang, Junbo Chen, Li Tan, Yan Wang, Zhichen Sun, Zhang Qi, Yushun Wan, Ying Zhu, Fang Liu, Kailang Wu, Yingle Liu, Jianguo Wu	26
20	CTLA-4 Limits Anti-CD20–Mediated Tumor Regression 2016 ·Clinical Cancer Research ·Zhenhua Ren, Jingya Guo, Jing Liao, Yan Luan, Zhida Liu, Zhichen Sun, (unknown), Yong Liang, Hua Peng, Yang‐Xin Fu	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact